$3.540
-0.310 (-8.76%)收盤時
SHPH 資訊
SHPH 事件
Shuttle Pharmaceuticals Reveals Extension of Letter of Intent with Molecule.ai
Shuttle Pharmaceuticals Holdings announced the execution of a non-binding letter of Intent with Molecule.ai. Molecule.ai, an artificial intelligence company founded by AI scientist and researcher Dr. ZT Zhang, PhD, announced the execution of a letter of Intent to acquire Molecule.ai and its platform, the company said in a statement. Shuttle will acquire all of the rights, title and interests Molecule.ai has free and clear of all liens. Shuttle will assume all liabilities in respect of Molecule.ai and at Closing, Molecule.ai shall have no further obligations or liabilities thereunder. Molecule.ai will extend the current AI model and platform to support Drug-Target Interaction. Molecule.ai will add first version of Agentic AI mode that enables an automatic workflow for drug discovery. Molecule.ai will serve as lead liaison and headhunter, leveraging its relationships in the artificial intelligence community to recruit additional employees and strengthen the team. As consideration for the purchase and the Transaction, and Shuttle's assumption of its obligations and liabilities, Shuttle shall pay to Molecule.ai, at closing, a purchase price of $10M payable, subject to the completion of the milestones, in a combination of cash and common shares of Shuttle. Consideration will be paid to Molecule.ai based upon certain milestones to be determined by both parties.
Shuttle Pharmaceuticals to purchase Molecule.ai for $10 million
Shuttle Pharmaceuticals announced the execution of a letter of intent to acquire Molecule.ai and its platform. The platform enables researchers to shorten development timelines, reduce costs, and increase the likelihood of identifying successful therapeutic candidates. Shuttle will acquire all of the rights, title and interests Molecule.ai has free and clear of all liens. Shuttle will assume all liabilities in respect of Molecule.ai and at closing, Molecule.ai shall have no further obligations or liabilities thereunder. Molecule.ai will extend the current AI model and platform to support drug-target interaction. Molecule.ai will add first version of agentic AI mode that enables an automatic workflow for drug discovery. Molecule.ai will serve as lead liaison and headhunter, leveraging its relationships in the artificial intelligence community to recruit additional employees. As consideration for the purchase and the transaction, and Shuttle's assumption of its obligations and liabilities, Shuttle shall pay to Molecule.ai, at closing, a purchase price of $10M payable, subject to the completion of the milestones, in a combination of cash and common shares of Shuttle. Consideration will be paid to Molecule.ai based upon certain milestones to be determined by both parties.
Shuttle Pharmaceuticals says reverse stock split to become effective June 16
Shuttle Pharmaceuticals announced that the reverse stock split will become effective on June 16, at 12:01 a.m., Eastern Time. The company's common stock will continue to trade on The Nasdaq Capital Market under the existing symbol "SHPH" and will begin trading on a split-adjusted basis when the market opens on June 16. At the effective time of the reverse stock split, every 25 shares of the company's issued and outstanding common stock will be automatically reclassified and combined into 1 share of common stock. This will reduce the number of issued and outstanding shares of common stock from 26,210,037 shares to approximately 1,048,401 shares, without giving effect to rounding
Shuttle Pharmaceuticals announces 25-for-1 proposed reverse stock split
Shuttle Pharmaceuticals announces that its Board of Directors have approved a proposed reverse stock split of its common stock at a ratio of 25-for-1. The proposed action remains subject to approval by Nasdaq and, if approved, the Company will issue a subsequent announcement disclosing the effective date.
Shuttle Pharmaceuticals appoints George Scorsis as chairman
Shuttle Pharmaceuticals announced the appointment of George Scorsis as the chairman of the board of directors. Scorsis has served as director of the company since February. Scorsis has over 25 years of experience leading companies in alcohol, energy drinks and Biotech.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。